title: Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
abstract: BACKGROUND
  Induction therapy has been recently adopted for intestinal transplant.
  
  
  METHODS
  We compared during first 30 days post-transplantation 29 recipients, allocated in two groups, treated with Daclizumab (Zenapax) or Alemtuzumab (Campath-1H).
  
  
  RESULTS
  During first month, 45% of Daclizumab recipients experienced six acute cellular rejections (ACRs) of mild degree, while 63% of them developed an infection requiring treatment. We found three acute cellular rejections in 17.6% of Alemtuzumab recipients, two with moderate degree; 64.7% of them required treatment for infection.
  
  
  CONCLUSIONS
  Graft and patient 3-years cumulative survival rate were not significantly different between groups. Alemtuzumab seems to offer a better immunosuppression during first month.
authors.affiliation: Liver and Multiorgan Transplant Unit, S.Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. augustola@yahoo.com
authors.forename: A
authors.initials: A
authors.lastname: Lauro
authors.forename: A
authors.initials: A
authors.lastname: Amaduzzi
authors.forename: A
authors.initials: A
authors.lastname: Dazzi
authors.forename: G
authors.initials: G
authors.lastname: Ercolani
authors.forename: C
authors.initials: C
authors.lastname: Zanfi
authors.forename: L
authors.initials: L
authors.lastname: Golfieri
authors.forename: G L
authors.initials: GL
authors.lastname: Grazi
authors.forename: M
authors.initials: M
authors.lastname: Vivarelli
authors.forename: M
authors.initials: M
authors.lastname: Cescon
authors.forename: G
authors.initials: G
authors.lastname: Varotti
authors.forename: M
authors.initials: M
authors.lastname: Del Gaudio
authors.forename: M
authors.initials: M
authors.lastname: Ravaioli
authors.forename: A
authors.initials: A
authors.lastname: Siniscalchi
authors.forename: S
authors.initials: S
authors.lastname: Faenza
authors.forename: A
authors.initials: A
authors.lastname: D'Errico
authors.forename: M
authors.initials: M
authors.lastname: Di Simone
authors.forename: L
authors.initials: L
authors.lastname: Pironi
authors.forename: A D
authors.initials: AD
authors.lastname: Pinna
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000077561:Daclizumab; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007422:Intestines / Q000637:transplantation*; D008297:Male; D011184:Postoperative Period; D014184:Transplantation, Homologous; D014781:Viscera / Q000637:transplantation*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D000077561:Daclizumab